Top neurology stories of 2024: The end of Aduhelm, misconduct in the NIH and more

Healio Neurology looks back at the most-viewed stories during the past year. Highlights include Biogen’s discontinuation of Aduhelm and a former NIH neuroscience director found guilty of research misconduct.

Read these and more below:

Biogen elects to discontinue Aduhelm

In February, Biogen announced a “reprioritization of resources,” which meant discontinuing production of Aduhelm for Alzheimer’s disease, choosing to advance Leqembi instead. Read more.

NIH finds former neuroscience director guilty of research misconduct

Eliezer Masliah, MD, former director of the division of neuroscience at the National Institute on Aging, was found to have committed falsification and/or fabrication involving repeated use and relabeling of figure panels in two publications. Read more.

Donanemab gets nod from FDA committee for early-stage Alzheimer’s

The Peripheral and Central Nervous System Drugs Advisory Committee ruled unanimously in June that the once-per-month, 30-minute infusion was effective to treat those with mild cognitive impairment and mild dementia stages of the condition. Read more.

Relyvrio pulled from markets in US, Canada

In early April, Amylyx Pharmaceuticals Inc. decided to remove Relyvrio, its amyotrophic lateral sclerosis drug due to results of the phase 3 PHOENIX trial which found the treatment nonsuperior to placebo at 48 weeks. Read more.

Participation in football linked to poor outcomes later in life

Researchers from Boston University’s Chronic Traumatic Encephalopathy Center found, among men who played American football, exposure to the sport at a younger age was strongly associated with worse cognitive performance. Read more.

Timolol nasal spray part of ‘new paradigm’ in migraine treatment

Headache experts John C. Hagan III, MD, FACS, FAAO and Steven C. Kosa, MD, advocate for timolol 0.5% eye drops, administered in a spray formulation, as a novel solution to acute migraine care. Read more.